Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management

Reuters11-25

Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management

Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586418184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586418184","market":"nz","top_or_hot":-1,"title":"Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 05:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6yrhcx:1","article_id":"2586418184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586418184","pubTimestamp":1764020727,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc.","BK4082":"医疗保健设备"},"translate_title":"Vivani Medical Inc.推出用于慢性体重管理的皮下索马鲁肽植入物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management\n    \n\n        Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586418184","isCrawlerRequest":true}